Details of issuance or disposal
Exercise status of the 10th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Shares delivered during the month: 160,000 (160,000 new shares; 0 treasury shares transferred)
The lower thin line represents the existing number of shares to which these shares will be added.
Shares delivered during the month: 160,000; exercise ratio against the total number issued: 1.9%. Exercise ratio subject to the exercise restriction: 1.6%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the 10th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 160,000 (160,000 new shares; 0 treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 13 February 2026) |
| Dilution Rate | Shares delivered during the month: 160,000; exercise ratio against the total number issued: 1.9%. Exercise ratio subject to the exercise restriction: 1.6% |
| Total number of issued shares | 16,778,500 shares (as of the end of the preceding month) → 16,938,500 shares (calculated figure reflecting the new shares delivered as of month-end) |
| Exercise price | Exercise price during the month: ¥107–¥110. Details of the adjustment provisions: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 82,700; exercised during the month: 1,600; unexercised at the end of the preceding month: 39,200; unexercised at month-end: 37,600 |
| Procedures under the Corporate Code of Conduct | Reports compliance with the exercise restriction under Article 434 of the Listing Regulations. Exercise ratio subject to the exercise restriction: 1.6% |
| Most recent equity financing | Issued on 13 February 2026: Series 10 Stock Acquisition Rights with EVO FUND as the allottee, subject to an exercise-price adjustment provision |
Items this document does not state (19)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report the monthly exercise status of the Series 10 Stock Acquisition Rights in September 2026.